Annals of Coloproctology

Original Articles

Epidermal Growth Factor Receptor Mutations in Colorectal Cancer Patients: Bo-Young Oh, Ryung-Ah Lee, Soon-Sup Chung, Kwang Ho Kim; J Korean Soc Coloproctol. 2011;27(3):127-132. Published online June 30, 2011; DOI: https://doi.org/10.3393/jksc.2011.27.3.127

3,859 View
37 Download
15 Citations

Purpose

The epidermal growth factor receptor (EGFR) plays an important role in tumorigenesis and tumor progression of colorectal cancer and leads to the activation of intracellular signaling pathways. The use of anti-EGFR-targeted therapy has increased for patients with colorectal cancer, but patients with EGFR mutations will be resistant to anti-EGFR-targeted therapy. The identification of gene mutations is critical in cancer treatment; therefore, the aim of this study is to investigate the incidences of EGFR mutations in colorectal cancer patients in Korea.

Methods

We retrospectively reviewed 58 colorectal cancer patients who underwent surgery between 2003 and 2006. We analyzed their EGFR mutations in four loci by DNA sequencing. In addition, we analyzed the correlation between the presence of EGFR mutation and patients' clinicopathologic features.

Results

Of the 58 patients, 35 patients were male and 23 were female. Their mean age was 63.28 ± 11.18 years. Two patients (3.45%) were diagnosed as stage Tis, 7 patients (12.07%) as stage I, 24 patients (41.38%) as stage II, 20 patients (34.48%) as stage III, and 5 patients (8.62%) as stage IV. As a result of mutational analysis, EGFR mutations on exon 20 were detected in 13 patients (22.41%, G→A transitions). No EGFR mutations were detected on exons 18, 19, and 21. EGFR mutation was increased in the earlier stage and in the absence of lymph node metastasis (P = 0.028).

Conclusion

The incidence of EGFR mutation in Korean colorectal cancer patients is 22.41%. In addition, EGFR mutation was significantly increased in the earlier stage and in the absence of lymph node metastasis.

Citations

Citations to this article as recorded by

Identification of potential inhibitors for drug-resistant EGFR mutations in non-small cell lung cancer using whole exome sequencing data
Nagasundaram Nagarajan, Chittibabu Guda
Frontiers in Pharmacology.2024;[Epub] CrossRef
Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics
Claiborne W. Tydings, Bhuminder Singh, Adam W. Smith, Kaitlyn V. Ledwitch, Benjamin P. Brown, Christine M. Lovly, Allison S. Walker, Jens Meiler
Protein Science.2024;[Epub] CrossRef
Gut-associated lymphoid tissue carcinoma analyzed using next-generation sequencing: A case report
Naomi Sato, Sadahide Ono, Kurodo Kamiya, Noriyuki Uesugi, Fumiyoshi Fujishima, Hiroshi Kawachi, Tamotsu Sugai
Pathology - Research and Practice.2024; 263: 155621. CrossRef
Diatom-Based Nanomedicine for Colorectal Cancer Treatment: New Approaches for Old Challenges
Chiara Tramontano, Luca De Stefano, Ilaria Rea
Marine Drugs.2023; 21(5): 266. CrossRef
Pharmacophore-Based Virtual Screening and In-Silico Explorations of Biomolecules (Curcumin Derivatives) of Curcuma longa as Potential Lead Inhibitors of ERBB and VEGFR-2 for the Treatment of Colorectal Cancer
Syeda Abida Ejaz, Mubashir Aziz, Mohamed Fawzy Ramadan, Ammara Fayyaz, Muhammad Sajjad Bilal
Molecules.2023; 28(10): 4044. CrossRef
Cutaneous adverse reactions resulting from targeted cancer therapies: histopathologic and clinical findings
Dylan Haynes, Eric E. Morgan, Emily Y. Chu
Human Pathology.2023; 140: 129. CrossRef
Genomic landscape of locally advanced rectal adenocarcinoma: Comparison between before and after neoadjuvant chemoradiation and effects of genetic biomarkers on clinical outcomes and tumor response
Tae Hoon Lee, Bum‐Sup Jang, Ji Hyun Chang, Eunji Kim, Jeong Hwan Park, Eui Kyu Chie
Cancer Medicine.2023; 12(14): 15664. CrossRef
Targeted Therapies in Colorectal Cancer: Recent Advances in Biomarkers, Landmark Trials, and Future Perspectives
Joao Manzi, Camilla O. Hoff, Raphaella Ferreira, Agustin Pimentel, Jashodeep Datta, Alan S. Livingstone, Rodrigo Vianna, Phillipe Abreu
Cancers.2023; 15(11): 3023. CrossRef
NRAS mutant E132K identified in young-onset sporadic colorectal cancer and the canonical mutants G12D and Q61K affect distinct oncogenic phenotypes
Ryan Timothy D. Yu, Reynaldo L. Garcia
Scientific Reports.2020;[Epub] CrossRef
Predicting Response to Neoadjuvant Therapy in Colorectal Cancer Patients the Role of Messenger-and Micro-RNA Profiling
Alberto Izzotti, Chiara Ceccaroli, Marta Geretto, Filippo Grillo Ruggieri, Sara Schenone, Emilio Di Maria
Cancers.2020; 12(6): 1652. CrossRef
Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer
Marcel Wiesweg, Stefan Kasper, Karl Worm, Thomas Herold, Henning Reis, Linda Sara, Martin Metzenmacher, Annalena Abendroth, Kaid Darwiche, Clemens Aigner, Heiner H. Wedemeyer, Fabian A. Helfritz, Martin Stuschke, Brigitte Schumacher, Peter Markus, Andreas
Oncogene.2019; 38(16): 2953. CrossRef
Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer
Evangelos Koustas, Michalis V. Karamouzis, Chrysovalantou Mihailidou, Dimitrios Schizas, Athanasios G. Papavassiliou
Cancer Letters.2017; 396: 94. CrossRef
Lack of Mutations in Protein Tyrosine Kinase Domain Coding Exons 19 and 21 of the EGFR Gene in Oral Squamous Cell Carcinomas
Dhaval Tushar Mehta, Thangavelu Annamalai, Arvind Ramanathan
Asian Pacific Journal of Cancer Prevention.2014; 15(11): 4623. CrossRef
Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis
Shoude Zhang, Jia Chen, Hua Jiang, Haina Ma, Beibei Yang
European Journal of Clinical Pharmacology.2012; 68(5): 561. CrossRef
Are Mutations of the EGFR Gene Promising Predictive Markers for Anti-EGFR mAbs in Colorectal Carcinomas?
Dong-Guk Park
Journal of the Korean Society of Coloproctology.2011; 27(3): 103. CrossRef

Methodologic Evaluation of EGFR Expression in Colorectal Cancer.: Oh, Soo Youn , Yoon, Se Jin , Cheon, Seung Hui , Lee, Ryung Ah , Kang, Bo Young , Lee, Shi Nae , Chung, Soon Sup , Kim, Kwang Ho; J Korean Soc Coloproctol. 2006;22(2):75-80.

1,100 View
6 Download

Abstract PDF: PURPOSE
The epidermal growth factor receptor (EGFR) is a one of the transmembrane receptor proteins that play an important role in initiating tumor cell signaling and growth and is regarded as a promising target for cancer therapy. The EGFR expression rate has been reported to vary according to the detection method. The aims of this study were to evaluate the EGFR expression rate of a colorectal carcinoma by using immunohistochemical staining (IHC) and semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) and to analyze the correlation between these methods.
METHODS
EGFR expression was investigated in tissue sections from 33 patients with a colorectal adenocarcinoma by using IHC and semiquantitative RT-PCR. IHC was performed with antibodies in a 1:40 dilution and a 1:80 dilution. The results of the three detection methods were compared with one another.
RESULTS
The mean age of the patients was 61.9+/-12.2 years, and the male-to-female ratio was 1.2:1. The EGFR expression rates were 93.9% (31/33) in IHC with a 1:40 dilution, 87.9% (29/33) in IHC with a 1:80 dilution, and 66.7% (22/33) in RT-PCR. The result of IHC with a 1:40 dilution significantly correlated with the result of IHC with a 1:80 dilution (Pearson correlation 0.684, P<0.01). There was no correlation between semiquantitative RT-PCR and IHC (1:40 dilution, 1:80 dilution).
CONCLUSIONS
The EGFR expression obtained by using IHC was consistent with different antibody dilutions. The expression rate obtained by using RT-PCR was significantly lower than that obtained by using IHC, and there was no statistical correlation between the expressions of EGFR obtained by using RT-PCR and IHC. A standardization for EGFR detection methods is needed to draw any conclusion concerning their activity in colorectal cancer.

First
Prev
Page of 1
Next
Last

Search